Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CPRX – Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.
CPRX
$21.60
Name : Catalyst Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,634,660,096.00
EPSttm : 1.57
finviz dynamic chart for CPRX
Catalyst Pharmaceuticals, Inc.
$21.60
0.83%
$0.18

Float Short %

6.96

Margin Of Safety %

54

Put/Call OI Ratio

1.42

EPS Next Q Diff

0.07

EPS Last/This Y

0.72

EPS This/Next Y

0.25

Price

21.79

Target Price

34.29

Analyst Recom

1.14

Performance Q

-12.32

Relative Volume

1.99

Beta

0.68

Ticker: CPRX




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02CPRX24.880.260.024177
2025-06-03CPRX24.910.260.004234
2025-06-04CPRX25.280.240.164436
2025-06-05CPRX25.340.270.134743
2025-06-06CPRX25.860.260.044923
2025-06-09CPRX25.830.250.285113
2025-06-10CPRX26.30.250.045400
2025-06-11CPRX25.40.250.125541
2025-06-12CPRX24.290.250.435705
2025-06-13CPRX23.450.270.405832
2025-06-16CPRX23.660.290.025834
2025-06-17CPRX23.220.301.185688
2025-06-18CPRX22.730.280.325715
2025-06-20CPRX22.470.2714.425598
2025-06-23CPRX22.121.670.837004
2025-06-24CPRX22.061.630.737439
2025-06-25CPRX21.521.520.277680
2025-06-26CPRX21.871.470.997778
2025-06-27CPRX21.791.420.037859
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02CPRX24.90-3.3-11.62.10
2025-06-03CPRX24.91-3.3-10.72.10
2025-06-04CPRX25.28-3.3-6.82.10
2025-06-05CPRX25.36-3.3-10.12.10
2025-06-06CPRX25.86-3.3-5.52.10
2025-06-09CPRX25.84-3.3-11.22.10
2025-06-10CPRX26.31-3.3-6.02.10
2025-06-11CPRX25.40-3.3-20.12.10
2025-06-12CPRX24.29-3.3-22.82.10
2025-06-13CPRX23.53-3.3-19.52.10
2025-06-16CPRX23.67-3.3-9.22.10
2025-06-17CPRX23.20-3.3-16.32.10
2025-06-18CPRX22.81-3.3-15.72.10
2025-06-20CPRX22.48-3.3-14.92.10
2025-06-23CPRX22.11-3.3-15.42.10
2025-06-24CPRX22.06-3.3-11.62.10
2025-06-25CPRX21.52-3.3-17.92.10
2025-06-26CPRX21.87-3.3-6.32.10
2025-06-27CPRX21.79-3.3-12.12.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02CPRX-5.210.516.70
2025-06-03CPRX-5.210.516.70
2025-06-04CPRX-5.210.516.70
2025-06-05CPRX-5.210.516.70
2025-06-06CPRX-5.210.516.70
2025-06-09CPRX-5.210.516.70
2025-06-10CPRX-5.240.516.70
2025-06-11CPRX-6.830.516.62
2025-06-12CPRX-6.470.516.62
2025-06-13CPRX-6.470.516.62
2025-06-16CPRX-6.470.526.61
2025-06-18CPRX-6.590.526.61
2025-06-20CPRX-6.590.526.61
2025-06-23CPRX-6.590.526.61
2025-06-24CPRX-6.590.526.61
2025-06-25CPRX-6.590.526.61
2025-06-26CPRX-6.590.526.96
2025-06-27CPRX-6.590.526.96
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

0.45

Avg. EPS Est. Current Quarter

0.54

Avg. EPS Est. Next Quarter

0.52

Insider Transactions

-6.59

Institutional Transactions

0.52

Beta

0.68

Average Sales Estimate Current Quarter

139

Average Sales Estimate Next Quarter

138

Fair Value

33.52

Quality Score

93

Growth Score

100

Sentiment Score

54

Actual DrawDown %

18

Max Drawdown 5-Year %

-45.4

Target Price

34.29

P/E

13.9

Forward P/E

12.01

PEG

0.96

P/S

4.97

P/B

3.34

P/Free Cash Flow

9.93

EPS

1.57

Average EPS Est. Cur. Y​

2.1

EPS Next Y. (Est.)

2.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

36.91

Relative Volume

1.99

Return on Equity vs Sector %

0.9

Return on Equity vs Industry %

18.8

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

-0.06

EBIT Estimation

-12.1
Catalyst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 181
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
stock quote shares CPRX – Catalyst Pharmaceuticals, Inc. Stock Price stock today
news today CPRX – Catalyst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CPRX – Catalyst Pharmaceuticals, Inc. yahoo finance google finance
stock history CPRX – Catalyst Pharmaceuticals, Inc. invest stock market
stock prices CPRX premarket after hours
ticker CPRX fair value insiders trading